Takeda Pharmaceutical Company Limited (NYSE:TAK) Shares Sold by Sei Investments Co.

Sei Investments Co. reduced its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 29.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 222,887 shares of the company's stock after selling 93,071 shares during the quarter. Sei Investments Co.'s holdings in Takeda Pharmaceutical were worth $2,951,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also made changes to their positions in TAK. Sage Rhino Capital LLC boosted its holdings in Takeda Pharmaceutical by 14.9% in the fourth quarter. Sage Rhino Capital LLC now owns 11,840 shares of the company's stock valued at $157,000 after purchasing an additional 1,538 shares in the last quarter. Kovitz Investment Group Partners LLC boosted its holdings in shares of Takeda Pharmaceutical by 7.0% in the 3rd quarter. Kovitz Investment Group Partners LLC now owns 25,456 shares of the company's stock valued at $362,000 after buying an additional 1,670 shares in the last quarter. Aaron Wealth Advisors LLC grew its position in shares of Takeda Pharmaceutical by 7.2% in the 4th quarter. Aaron Wealth Advisors LLC now owns 25,000 shares of the company's stock valued at $331,000 after buying an additional 1,670 shares during the last quarter. EverSource Wealth Advisors LLC raised its stake in Takeda Pharmaceutical by 51.8% during the 4th quarter. EverSource Wealth Advisors LLC now owns 5,190 shares of the company's stock worth $69,000 after acquiring an additional 1,770 shares in the last quarter. Finally, HighTower Advisors LLC boosted its stake in Takeda Pharmaceutical by 1.5% in the fourth quarter. HighTower Advisors LLC now owns 124,439 shares of the company's stock valued at $1,648,000 after acquiring an additional 1,852 shares in the last quarter. Institutional investors and hedge funds own 9.17% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Separately, Morgan Stanley upgraded Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a research report on Wednesday, April 2nd.

Takeda Pharmaceutical Stock Performance

Shares of TAK stock traded down $0.34 during trading hours on Tuesday, hitting $14.05. The stock had a trading volume of 3,911,684 shares, compared to its average volume of 1,840,473. Takeda Pharmaceutical Company Limited has a twelve month low of $12.58 and a twelve month high of $15.37. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72. The firm has a market capitalization of $44.69 billion, a PE ratio of 35.11, a PEG ratio of 0.24 and a beta of 0.39. The stock's 50 day moving average is $14.40 and its 200 day moving average is $13.91.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. As a group, research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.